
Sign up to save your podcasts
Or


A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science, say Portfolio Manager Andy Acker and Research Analyst Vish Sridharan.
By Janus Henderson Investors4.7
1414 ratings
A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science, say Portfolio Manager Andy Acker and Research Analyst Vish Sridharan.

522 Listeners

963 Listeners

4,345 Listeners

1,933 Listeners

292 Listeners

652 Listeners

2,116 Listeners

1,297 Listeners

6,097 Listeners

9,922 Listeners

1,569 Listeners

448 Listeners

209 Listeners

78 Listeners

0 Listeners

3 Listeners